10-Q: Neurocrine Biosciences Reports Strong Product Sales Amid Increased R&D Investment and Pipeline Progress

Neurocrine Biosciences announced increased net product sales for the first half of 2025, driven by INGREZZA and the recent launch of CRENESSITY, despite higher operating expenses and a Phase 3 study setback for valbenazine in schizophrenia.

Summary

• Total revenues for the six months ended June 30, 2025, increased to $1,260.1 million, up from $1,105.5 million in the comparable period of 2024.
• Net product sales reached $1,245.7 million for the first six months of 2025, compared to $1,092.8 million in the prior year, primarily due to increased INGREZZA sales and the launch of CRENESSITY.
• INGREZZA net product sales were $1,169.6 million for the first six months of 2025, up from $1,085.5 million in 2024, driven by strong patient demand.
• CRENESITY, launched in December 2024, generated $67.7 million in net product sales for the first six months of 2025.
• Operating expenses significantly increased to $1,090.9 million for the first six months of 2025, from $860.8 million in 2024, due to higher R&D and SG&A investments.
• Research and development expenses rose to $507.5 million for the first six months of 2025, compared to $350.5 million in 2024, reflecting increased investment in late-stage programs (osavampator, NBI-1117568) and preclinical/gene therapy programs.
• Selling, general, and administrative expenses increased to $562.8 million for the first six months of 2025, from $485.1 million in 2024, driven by commercial organization expansion and CRENESSITY launch activities.
• Net income for the six months ended June 30, 2025, was $115.4 million, a slight increase from $108.4 million in 2024.
• Diluted earnings per share increased to $1.13 for the first six months of 2025, up from $1.04 in 2024.
• Cash flows from operating activities decreased to $166.8 million for the first six months of 2025, from $194.9 million in 2024, reflecting increased investments.
• A Phase 3 clinical study for valbenazine for the adjunctive treatment of schizophrenia did not meet its primary endpoint.
• The company initiated Phase 3 clinical studies for NBI-1117568 in schizophrenia and osavampator in Major Depressive Disorder (MDD).
• New Phase 1 clinical studies were initiated for NBIP-1435 (CAH), NBI-921355 (epilepsy), and NBI-1140675 (VMAT2 inhibitor).
• The Board of Directors authorized a new $500.0 million share repurchase program in February 2025, with $332.3 million remaining as of June 30, 2025.
• INGREZZA qualifies for the small biotech exception under the Medicare Drug Price Negotiation Program, exempting it from selection until 2027 for initial price applicability in 2029.
• Legal proceedings include patent infringement suits against Zydus Lifesciences Global FZE regarding generic INGREZZA SPRINKLE and a dismissed patent invalidity suit against Spruce Biosciences, Inc.

Sentiment

Score: 6

Explanation: The filing presents a mixed but generally positive outlook. Strong revenue growth from key products and significant pipeline advancements are positive indicators. However, the substantial increase in operating expenses, resulting in a decrease in operating income, and the failure of a Phase 3 clinical trial for a specific indication, temper the overall sentiment. The ongoing legal challenges and the need for potential future capital raises also add a layer of caution, but the company's existing cash position and strategic share repurchases suggest financial stability.

Positives

• Net product sales increased significantly to $1,245.7 million for the first six months of 2025, driven by strong performance of INGREZZA and the successful launch of CRENESSITY.
• INGREZZA net product sales grew to $1,169.6 million, demonstrating continued strong patient demand.
• CRENESITY, a first-in-class FDA-approved treatment for CAH, generated $67.7 million in sales in its initial months post-launch.
• Initiated two Phase 3 clinical studies for NBI-1117568 (schizophrenia) and osavampator (MDD), indicating significant pipeline advancement.
• Expanded early-phase pipeline with three new Phase 1 clinical studies for NBIP-1435, NBI-921355, and NBI-1140675.
• Positive top-line data from the Phase 4 KINECT-PRO study for INGREZZA demonstrated clinically meaningful and sustained effects on TD patients.
• INGREZZA received the small biotech exception under the Medicare Drug Price Negotiation Program, providing exemption from selection until 2027.
• Expanded formulary access for INGREZZA to approximately 70% of TD and Huntington's disease Medicare beneficiaries, supporting long-term growth.
• The company authorized a new $500.0 million share repurchase program, signaling confidence in financial health and commitment to shareholder returns.
• The One Big Beautiful Bill Act (OBBBA) signed into law makes 100% bonus depreciation and domestic research cost expensing permanent, which could positively impact future tax liabilities.

Negatives

• Operating income decreased to $169.2 million for the first six months of 2025, down from $244.7 million in 2024, despite revenue growth, due to significantly higher operating expenses.
• Research and development expenses increased substantially, impacting profitability, reflecting high investment costs in pipeline development.
• Selling, general, and administrative expenses increased due to continued investment in commercial organization and launch activities, contributing to higher overall operating costs.
• A Phase 3 study of valbenazine for the adjunctive treatment of schizophrenia did not meet its primary endpoint, representing a clinical setback for that specific indication.
• Cash flows from operating activities decreased, indicating higher cash utilization for operational investments.
• The company faces ongoing patent litigation regarding INGREZZA SPRINKLE against Zydus Lifesciences Global FZE, which could lead to increased legal costs and potential market competition from generics.

Risks

• Inability to successfully commercialize INGREZZA or CRENESSITY, or any future approved product candidates.
• Lack of physician and patient acceptance of CRENESSITY, or ineffective sales and marketing efforts, could limit revenue generation.
• Intense competition from existing products (e.g., AUSTEDO, off-label uses) and other development-stage programs could reduce demand for products.
• Government and third-party payors may impose sales and pharmaceutical pricing controls, limit coverage/reimbursement, or make adverse policy decisions (e.g., IRA, Medicare Part D changes, 340B program expansion, state PDABs).
• Technological uncertainty in product development means potential products may be ineffective, cause harmful side effects, fail regulatory approval, or be uneconomical.
• Clinical trials may be delayed for safety or other reasons, or fail to demonstrate safety and efficacy, preventing or delaying regulatory approval.
• Increased organizational size and rapid growth may lead to difficulties in management, recruitment, and integration of personnel and systems (e.g., ERP system implementation).
• Transformation of R&D strategies to include biologics development requires substantial investment and expertise, with risks of development failure or delays due to manufacturing complexity and evolving regulatory requirements.
• Inability to retain and recruit qualified scientists and other employees, or loss of key senior executives, could delay development efforts or impact commercialization.
• Use of approved products or those of collaborators could be associated with side effects or adverse events, negatively impacting demand or regulatory approval.
• Dependence on a limited number of third-party suppliers for production and packaging of products and product candidates poses risks of supply disruption or substandard performance.
• Reliance on current collaborators for development and commercialization of products and product candidates introduces risks of lack of control, disagreements, or termination of agreements.
• Lack of internal manufacturing capabilities makes the company dependent on contract manufacturers, exposing it to risks of production difficulties, quality control issues, and regulatory non-compliance.
• Defaulting on obligations or violating terms of third-party licenses could lead to loss of rights to core technologies and drug candidates or payment of damages.
• Concentration of customers (four customers represent over 90% of gross product sales, one for CRENESSITY) makes the business vulnerable to loss of a significant customer.
• Need for additional capital in the future, with no assurance that adequate funding will be available on acceptable terms, potentially leading to inability to fund business plans.
• Expected increase in expenses for the foreseeable future, making it challenging to sustain growth and profitability.
• Potential for the technologies used or drug targets selected to infringe on third-party patents or proprietary rights, leading to costly litigation or inability to commercialize products.
• Business operations may lead to disputes, claims, and lawsuits, which can be costly, time-consuming, and materially impact financial position.
• Risk of employee or independent contractor misconduct, including non-compliance with regulatory standards, fraud, or improper use of confidential information.
• Potential product liability exposure far in excess of insurance coverage, which could decrease cash reserves and stock price.
• Activities involve hazardous materials, with liability for any resulting contamination or injuries.
• Stringent and changing obligations related to data privacy and information security (e.g., GDPR, CCPA, AI use) could lead to compliance costs, regulatory investigations, litigation, and reputational harm.
• Unfavorable geopolitical and macroeconomic developments (e.g., tariffs, trade barriers, conflicts) could adversely affect business, supply chain, and financial condition.
• Failure to obtain or maintain orphan drug designation or other regulatory exclusivity for product candidates could harm competitive position.
• Changes in the FDA, U.S. Patent and Trademark Office, or other government agencies could hinder their ability to perform normal business functions, delaying product development and commercialization.
• Potential liability if a regulatory authority determines the company is promoting products for off-label uses, leading to significant civil or criminal sanctions.

Future Outlook

The company anticipates continued significant operating and capital expenditures to commercialize INGREZZA and CRENESSITY, seek regulatory approvals for product candidates, develop and manufacture new products, and expand internal systems and personnel. Future capital requirements are substantial and depend on factors like commercial success, R&D progress, regulatory approvals, and litigation costs. The company believes existing capital resources and anticipated product sales will be sufficient for at least the next 12 months, but may seek additional funding through equity, debt, or strategic alliances.

Management Comments

• Our simple purpose is to relieve suffering for people with great needs, but few options.
• Key elements of our commercial strategy include maximizing the opportunities in INGREZZA and CRENESSITY through consistent and effective commercial execution.
• We aim for continued development of valbenazine as the best-in-class treatment for new patient populations.
• We intend to lead the evolving understanding of vesicular monoamine transporter 2 (VMAT2) biology and its role in disease.
• We are still evaluating the effects of the One Big Beautiful Bill Act (OBBBA) and will reflect them in our Quarterly Report for the quarter ending September 30, 2025.
• We currently believe that none of the claims or actions pending against us is likely to have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations, but given the unpredictability inherent in litigation, we cannot predict the outcome of these matters.

Industry Context

Neurocrine Biosciences operates in the highly competitive and rapidly evolving biopharmaceutical industry, specifically focusing on neurological, neuroendocrine, and neuropsychiatric disorders. The company's strategy involves maximizing existing product opportunities (INGREZZA, CRENESSITY) while investing heavily in a diversified pipeline, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapy. The industry faces increasing pressure from government and third-party payors regarding drug pricing and reimbursement, as evidenced by the Inflation Reduction Act (IRA) and state-level initiatives. The company's qualification for the small biotech exception under Medicare drug price negotiation provides a temporary competitive advantage for INGREZZA compared to competitors like Teva's AUSTEDO, which has been selected for negotiation. The shift towards biologics development aligns with broader industry trends but introduces new manufacturing and regulatory complexities. The ongoing legal challenges related to generic competition for key products highlight the constant intellectual property battles within the pharmaceutical sector.

Comparison to Industry Standards

• INGREZZA competes directly with Teva Pharmaceuticals Industries' AUSTEDO (deutetrabenazine) for tardive dyskinesia and chorea associated with Huntington's disease. AUSTEDO XR, a once-daily dosing, was introduced in February 2023, intensifying competition. AUSTEDO and AUSTEDO XR have been selected for Medicare drug negotiation in 2025, potentially increasing competitive pressure on INGREZZA, although INGREZZA has a small biotech exception until 2027.
• CRENESITY competes with high-dose corticosteroid monotherapy, the current standard of care for CAH, and other companies' clinical development programs targeting CAH.
• The company's investigational treatments for schizophrenia and depression will compete with numerous approved anti-psychotic and anti-depressant medications and other development-stage programs from various companies.
• Compared to many competitors, Neurocrine Biosciences has substantially smaller capital resources, sales and marketing experience, R&D capabilities, regulatory experience, and production facilities, which could pose a competitive disadvantage.
• The company's shift into biologics development, including gene therapies, aligns with industry innovation but contrasts with its historical small molecule focus, requiring new expertise and infrastructure compared to established biologics developers.

Management Changes

Corporate Governance

Legal Proceedings

• In March 2025, received notice from Zydus Lifesciences Global FZE regarding an Abbreviated New Drug Application (ANDA) seeking approval for a generic version of INGREZZA SPRINKLE, alleging patent invalidity/non-infringement.
• Filed suit in April 2025 in the U.S. District Court for the District of Delaware against Zydus Pharmaceuticals (USA) Inc. and its affiliates to prevent the sale of generic INGREZZA SPRINKLE.
• Filed suit in April 2025 in the U.S. District Court for the District of New Jersey against Zydus seeking to prevent the sale of generic INGREZZA SPRINKLE.
• Filed suit in January 2025 in the U.S. District Court for the District of Delaware against Spruce Biosciences, Inc. seeking a declaratory judgment of invalidity of one of Spruce's patents; the case was dismissed without prejudice in June 2025 for lack of case or controversy.
• Initiated administrative proceedings against another Spruce patent in the U.S. Patent and Trademark Office and both judicial and administrative proceedings against Spruce patents in other jurisdictions.

Related Party Transactions

• The equity investment in Voyager Therapeutics, Inc. became subject to the equity method of accounting, and Voyager became a related party, following the purchase of 4.4 million shares of Voyager common stock in 2023 (2023 Voyager Shares), which, together with 2019 Voyager Shares, resulted in approximately 19.9% ownership of Voyager's voting stock.
• Jude Onyia, Ph.D., Chief Scientific Officer of Neurocrine Biosciences, was appointed to Voyager's board of directors as part of the 2023 Voyager Agreement.

Stakeholder Impact

• Shareholders: Impacted by stock price volatility due to financial results, pipeline updates (including setbacks), and ongoing legal/regulatory risks. Share repurchase programs aim to enhance shareholder value.
• Employees: Increased headcount and expansion of commercial teams indicate growth opportunities, but rapid growth may pose management and retention challenges.
• Customers (Patients & Physicians): Benefit from new product launches (CRENESITY) and expanded formulary access for existing products (INGREZZA). Potential impact from drug pricing controls and reimbursement policies.
• Suppliers & Manufacturers: Continued reliance on a limited number of third-party suppliers and contract manufacturers for product production and development, posing supply chain risks.
• Collaborators: Ongoing collaboration agreements with companies like Nxera, Takeda, Xenon, Voyager, Sanofi, MTPC, and AbbVie are crucial for pipeline development and commercialization, with associated milestone payments and royalty streams.

Next Steps

• Continue commercialization efforts for INGREZZA and CRENESSITY, including expanding sales teams and market access.
• Advance Phase 3 clinical studies for NBI-1117568 in schizophrenia and osavampator in MDD.
• Continue Phase 1 clinical studies for NBIP-1435 (CAH), NBI-921355 (epilepsy), and NBI-1140675 (neurological/neuropsychiatric conditions).
• Evaluate the impact of the One Big Beautiful Bill Act (OBBBA) on financial statements for the quarter ending September 30, 2025.
• Manage ongoing patent litigation against Zydus Lifesciences Global FZE regarding generic INGREZZA SPRINKLE.
• Continue administrative and judicial proceedings against Spruce Biosciences patents.
• Potentially seek additional funding through public/private equity or debt financing to support future growth and R&D programs.
• Continue share repurchases under the authorized $500.0 million program.

Key Dates

Recommendation

Neurocrine Biosciences demonstrates strong commercial execution with significant revenue growth from INGREZZA and the successful launch of CRENESSITY. The company is actively investing in its pipeline, with two programs entering Phase 3, which signals future growth potential. However, the substantial increase in operating expenses, leading to a decrease in operating income, and the recent failure of a Phase 3 study for valbenazine in schizophrenia, introduce concerns about profitability and pipeline efficiency. The ongoing patent litigation and the inherent risks of drug development and commercialization, coupled with a highly competitive and regulated market, suggest a 'hold' recommendation. While the company has a solid foundation and strategic initiatives like share repurchases, the increased costs and clinical setback warrant a cautious approach until there is clearer evidence of sustained profitability and successful pipeline progression.

Keywords

Neurocrine Biosciences, Biopharmaceutical, Neurology, Neuropsychiatry, Neuroendocrine, Tardive Dyskinesia, Huntington's Disease, Congenital Adrenal Hyperplasia, Major Depressive Disorder, Schizophrenia, Epilepsy, Gene Therapy, INGREZZA, CRENESITY, Valbenazine, Crinecerfont, Osavampator, NBI-1117568, Clinical Trials, Drug Development, FDA Approval, SEC Filing, 10-Q, Financial Results, R&D, Commercialization, Share Repurchase, Medicare Drug Price Negotiation Program, Patent Litigation, Biologics